GM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative Neoplasm

Pulmonary alveolar proteinosis (PAP) is classified as autoimmune, secondary, or genetic. We herein describe a 69-year-old man with autoimmune PAP, simultaneously diagnosed with myeloproliferative neoplasm (MPN). Two years after the diagnosis, the MPN progressed to acute myeloid leukemia, and the pat...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2017/02/15, Vol.56(4), pp.435-439
Main Authors: Imoto, Naoto, Harunori, Nakashima, Furukawa, Katsuya, Tange, Naoyuki, Murase, Atsushi, Hayakawa, Masaya, Ichihara, Masatoshi, Iwata, Yosuke, Kosugi, Hiroshi
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Aged
Alveoli
Autoantibodies
Autoantibodies - blood
Autoimmune Diseases - complications
Autoimmune Diseases - diagnosis
Autoimmune Diseases - pathology
Biopsy
Case Report
Chemotherapy
Disease Progression
Fatal Outcome
GM-SCF autoantibody
Granulocyte-macrophage colony-stimulating factor
Granulocyte-Macrophage Colony-Stimulating Factor - immunology
Hematology
Hemorrhage
Humans
Internal medicine
Leukemia
Leukemia, Myeloid, Acute - etiology
Lung - pathology
Male
Malignancy
Myeloid leukemia
Myeloproliferative Disorders - etiology
myeloproliferative neoplasm
pulmonary alveolar proteinosis
Pulmonary Alveolar Proteinosis - complications
Pulmonary Alveolar Proteinosis - diagnosis
Pulmonary Alveolar Proteinosis - pathology
Radiography, Thoracic
Remission
Tomography, X-Ray Computed
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary alveolar proteinosis (PAP) is classified as autoimmune, secondary, or genetic. We herein describe a 69-year-old man with autoimmune PAP, simultaneously diagnosed with myeloproliferative neoplasm (MPN). Two years after the diagnosis, the MPN progressed to acute myeloid leukemia, and the patient died from an alveolar hemorrhage during remission induction chemotherapy. Throughout the clinical course, no progression of PAP was observed, despite the progression to leukemia. There are few reports of autoimmune PAP with hematological malignancy, and this case demonstrated that an evaluation for GM-CSF autoantibodies is important for distinguishing the autoimmune and secondary forms of PAP, even if the patient has hematological malignancy.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.56.6920